Abstract: TH-PO0953
Haptoglobin Polymorphism as a Guide to Personalized Therapy and Surveillance in Kidney Transplantation: A Multidomain Risk Stratification Approach
Session Information
- Transplantation: Clinical - Glomerular Diseases, Infections, and Rejection
November 06, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Transplantation
- 2102 Transplantation: Clinical
Authors
- Ural, Zeynep, Kirikkale Yüksek Ihtisas Hospital, Department of Nephrology,, Kirikkale, Turkey
- Helvaci, Ozant, Gazi University Faculty of Medicine, Department of Nephrology, Ankara, Turkey
- Gonen, Sevim, Gazi University Faculty of Medicine, Tissue Typing Laboratory, Ankara, Turkey
- Derici, Ulver, Gazi University Faculty of Medicine, Department of Nephrology, Ankara, Turkey
Background
Haptoglobin (Hp) is a genetically polymorphic plasma glycoprotein with potent antioxidant and immunomodulatory functions. Its phenotypes (Hp 1-1, Hp 1-2, Hp 2-2) influence susceptibility to oxidative stress and inflammatory responses, particularly in immunocompromised individuals. While the impact of Hp polymorphism on infectious outcomes has been partially explored, its broader implications for post-transplant risk domains remain undefined. This study aimed to evaluate the role of Hp genotype in predicting long-term cardiovascular (CV), metabolic, oncologic, and immunologic outcomes—as well as graft survival—in kidney transplant recipients (KTRs).
Methods
We conducted a retrospective, single-center cohort study involving 229 adult KTRs. Hp phenotypes were determined Clinical endpoints included incidence of cardiovascular disease (CVD), diabetes mellitus (DM), malignancy, rejection, and 5-year graft survival. Associations were assessed using chi-square tests and multivariable
Results
Among 229 genotyped kidney transplant recipients, 119 (52.0%) had Hp2-2, 93 (40.6%) had Hp1-2, and 17 (7.4%) had Hp1-1. The Hp2-2 group demonstrated significantly higher prevalence of cardiovascular disease (p=0.018) and diabetes mellitus (p=0.022) compared to other genotypes. Although not statistically significant, malignancy, biopsy-proven acute rejection, and five-year end-stage renal disease rates were also higher in the Hp2-2 group.
Conclusion
Hp 2-2 genotype is strongly associated with adverse cardiovascular, metabolic, oncologic, and immunologic outcomes in kidney transplant recipients. This genotype also predicts poorer graft survival. Integrating Hp polymorphism into routine genetic assessment may guide personalized therapy and surveillance, enabling stratified post-transplant care based on multi-domain risk. These findings highlight the clinical utility of genotype-driven decision-making in precision transplant nephrology.
Funding
- Private Foundation Support